Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

313.27
-2.0400-0.65%
Volume:316.64K
Turnover:98.29M
Market Cap:18.95B
PE:34.01
High:314.43
Open:313.89
Low:308.53
Close:315.31
52wk High:330.75
52wk Low:263.00
Shares:60.49M
Float Shares:60.49M
Volume Ratio:1.65
T/O Rate:0.52%
Dividend:4.60
Dividend Rate:1.47%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.96
PE(LYR):7.55

Loading ...

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

UnitedHealth - 95% of Medicare-Eligible Individuals to Have Access to Hmo Plan in 2027

THOMSON REUTERS
·
Oct 01

Unitedhealthcare 2027 Medicare Plans Focus on Affordability, Simplicity and a More Connected Healthcare Experience

THOMSON REUTERS
·
Oct 01

Unitedhealthcare: 2027 Plans Offer $0 Primary Care Visits, $0 Preventive Care, $0 Tier 1 Drug Copays

THOMSON REUTERS
·
Oct 01

Unitedhealthcare: Introduces 2027 Medicare Advantage Plans; About 90% of Eligible Consumers to Have Access to $0 Premium

THOMSON REUTERS
·
Oct 01

UnitedHealthcare, Aetna Say 2027 Medicare Advantage Plans to Offer More Limited Provider Networks

Reuters
·
Oct 01

Merck Schedules Third-Quarter Sales and Earnings Conference Call with Investors and Analysts

Reuters
·
Oct 01

Johnson & Johnson (JNJ) Stock Could Be Undervalued On Future Cash Flow

Simply Wall St.
·
Oct 01

Merck & Co Inc : Jefferies Raises Target Price to $177 from $175

THOMSON REUTERS
·
Oct 01

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

Nexsen reshapes leadership to drive growth in point-of-care diagnostics

TIPRANKS
·
Oct 01

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
Oct 01

Eli Lilly - Achieve-4: Foundayo Shows 16% Lower Mace-4 and 23% Lower Mace-3 Risk vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Eli Lilly - Foundayo Shows Smaller Egrf Reduction and Greater Albuminuria Reduction vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Estee Lauder Cos. Cl a Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements

GlobeNewswire
·
Oct 01